PET with the 89Zr-labeled transforming growth factor-β antibody fresolimumab in tumor models.

@article{Munnink2011PETWT,
  title={PET with the 89Zr-labeled transforming growth factor-β antibody fresolimumab in tumor models.},
  author={Thijs H. Oude Munnink and Marlous E A Arjaans and Hetty Timmer-Bosscha and Carolina P. Schr{\"o}der and Jan Willem Hesselink and Silke R. Vedelaar and Annemiek M E Walenkamp and Michael Reiss and Richard C. Gregory and Marjolijn N. Lub-de Hooge and Elisabeth G. E. de Vries},
  journal={Journal of nuclear medicine : official publication, Society of Nuclear Medicine},
  year={2011},
  volume={52 12},
  pages={2001-8}
}
UNLABELLED Transforming growth factor-β (TGF-β) promotes cancer invasion and metastasis and is therefore a potential drug target for cancer treatment. Fresolimumab, which neutralizes all mammalian active isoforms of TGF-β, was radiolabeled with (89)Zr for PET to analyze TGF-β expression, antibody tumor uptake, and organ distribution. METHODS (89)Zr was conjugated to fresolimumab using the chelator N-succinyldesferrioxamine-B-tetrafluorphenol. (89)Zr-fresolimumab was analyzed for conjugation… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 2 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 16 extracted citations

PET/CT-derived whole-body and bone marrow dosimetry of 89Zr-cetuximab.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine • 2015

TGF-β Antibody Uptake in Recurrent High-Grade Glioma Imaged with 89Zr-Fresolimumab PET.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine • 2015
View 3 Excerpts

References

Publications referenced by this paper.
Showing 1-10 of 32 references

Integrin-mediated activation of latent transforming growth factor β

Cancer and Metastasis Reviews • 2005
View 4 Excerpts
Highly Influenced

89Zr-bevacizumab PET imaging in renal cell carcinoma patients: feasibility of tumor VEGF quantification [abstract

SF Oosting, WB Nagengast, TH Oude Munnink
Available at: http://poster-submission.com/search/. Accessed November • 2011
View 2 Excerpts

Companies waver in efforts to target transforming growth factor beta in cancer.

Journal of the National Cancer Institute • 2009
View 1 Excerpt

Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine • 2009
View 2 Excerpts

Similar Papers

Loading similar papers…